Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
The Motley Fool
by newsfeedback@fool.com (Jake Lerch)March 4, 2026
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.
Verticals
financeinvesting
Originally published on The Motley Fool on 3/4/2026